Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA.
- Published in:
- Antiviral Therapy, 2023, v. 28, n. 6, p. 1, doi. 10.1177/13596535231220754
- By:
- Publication type:
- Article
Works matching IS 13596535 AND DT 2023 AND VI 28 AND IP 6
Results: 4
1
2
Dolutegravir and rilpivirine as successful initial antiretroviral therapy in a treatment-naive patient with HIV-1: A case report.
- Published in:
- Antiviral Therapy, 2023, v. 28, n. 6, p. 1, doi. 10.1177/13596535231218875
- By:
- Publication type:
- Article
3
RVX-208, an inducer of Apolipoprotein A-I, inhibits the particle production of hepatitis B virus through activation of cGAS-STING pathway.
- Published in:
- Antiviral Therapy, 2023, v. 28, n. 6, p. 1, doi. 10.1177/13596535231219639
- By:
- Publication type:
- Article
4
Waitlist-controlled trial of an online intervention to address mental health among older people living with HIV.
- Published in:
- Antiviral Therapy, 2023, v. 28, n. 6, p. 1, doi. 10.1177/13596535231216311
- By:
- Publication type:
- Article